<DOC>
	<DOCNO>NCT02049047</DOCNO>
	<brief_summary>Given high expression IGF-1R pAKT proteins thymoma tissue , able sensitize tumor mTOR inhibition , anticancer activity mTOR inhibitor , clinical evaluation thymoma thymic carcinoma seem interesting . Patients receive continuous treatment oral everolimus 10 mg daily . Efficacy safety profile Everolimus evaluate .</brief_summary>
	<brief_title>Study Everolimus Patients With Thymoma Thymic Carcinoma Previously Treated With Chemotherapy</brief_title>
	<detailed_description>Patients receive continuous treatment oral everolimus 10 mg daily . Study drug self-administered orally ( two 5 mg tablet ) daily fast state light fat-free meal . Each cycle consider 21 day treatment ; safety assess every 21 day . Tumor assessement do every two cycle . Treatment administer documented disease progression , unacceptable toxicity , patient refusal .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Thymoma</mesh_term>
	<mesh_term>Thymus Neoplasms</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Histological diagnosis invasive recurrent metastatic thymoma thymic carcinoma confirm pathologist . At least one prior platinumcontaining chemotherapy regimen . There limit number prior chemotherapy regimens receive . Progressive disease document entry study . Measurable disease , define least one lesion accurately measure least one dimension ( long diameter record ) great 20 mm conventional technique great 10 mm spiral CT scan . Patients must recover toxicity relate prior therapy least grade 1 ( define CTCAE 3.0 ) . No major surgery , radiation therapy , chemotherapy , biologic therapy ( include investigational agent ) , hormonal therapy ( replacement ) , within 4 week prior enter study . Life expectancy least 3 month . Performance status ( ECOG ) &lt; =2 Negative pregnancy test ( female reproductive year ) Adequate organ marrow function ( define ) Leukocytes &gt; =3,000/mm , Absolute neutrophil count &gt; =1,500/mm , Hemoglobin &gt; = 9 g/dL , Platelets &gt; = 100,000/mm , Total bilirubin &gt; = 1.5 x institutional upper limit normal ( ULN ) , AST ( SGOT ) /ALT ( SGPT ) &gt; = 3 x institutional ULN ( 5x LFT elevation due liver metastasis , ) Creatinine &lt; = 1.5 x institutional ULN Patients symptomatic brain metastasis . However , patient treatment brain metastasis whose brain metastatic disease status remain stable least 3 month without steroid may enrol discretion investigator . Major surgery , diagnostic surgery , within 4 week prior treatment Active , uncontrolled bacterial , viral , fungal infection , require systemic therapy Pregnant breast feed woman Previous ( within last 5 year ) current malignancy site , except adequately treat basal cell squamous cell skin cancer situ carcinoma cervix uteri Current enrollment participation another therapeutic clinical trial within 4 week precede treatment start . Other severe acute chronic medical psychiatric condition laboratory abnormality may increase risk associate study participation may interfere interpretation study result , judgement Investigator , would make patient inappropriate entry study could compromise protocol objective opinion Investigator and/or Sponsor .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>thymoma thymic carcinoma</keyword>
</DOC>